Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mathias J Rummel; Norbert Niederle; Georg Maschmeyer; G Andre Banat; Ulrich von Grünhagen; Christoph Losem; Dorothea Kofahl-Krause; Gerhard Heil; Manfred Welslau; Christina Balser; Ulrich Kaiser; Eckhart Weidmann; Heinz Dürk; Harald Ballo; Martina Stauch; Fritz Roller; Juergen Barth; Dieter Hoelzer; Axel Hinke; Wolfram Brugger

The Lancet (2013) - Comments
doi: 10.1016/s0140-6736(12)61763-2 issn: 0140-6736 pubmed: 23433739

Mathias J Rummel, Norbert Niederle, Georg Maschmeyer, G Andre Banat, Ulrich Von Grünhagen, Christoph Losem, Dorothea Kofahl-Krause, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Eckhart Weidmann, Heinz Dürk, Harald Ballo, Martina Stauch, Fritz Roller, Juergen Barth, Dieter Hoelzer, Axel Hinke, Wolfram Brugger